IDEXX LABORATORIES INC
IDXXNASDAQ🏆 #350 by market capEarnings Nov 2US Equity
$534.20▲ $5.18 (+0.97%)
LiveTrack IDXX
Get earnings, price moves & breaking news on Telegram
24h▲ 1.0%
7d▲ 2.4%
14d▲ 4.6%
30d▼ 3.7%
ytd▼ 21.0%
1y▼ 15.3%
🏦Market Cap
$42.14B
Mid Cap
📈Revenue Growth (YoY)
+10.4%
Healthy
📊Gross Margin
62.5%
High
💵FCF Margin
27.5%
Strong
⚖️P/S Ratio
9.2x
Elevated
Otter Score
96
Very Good
IDEXX LABORATORIES INC
IDXXAnalyst Ratings
Price
$534.20
Total
23
Raised
1
Lowered
3
Avg PT
$665.00
H / L
$710 / $620
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
Barclays | Reiterated | Overweight | 2026-08-11 | $710.00 | +32.90% |
UBS | Reiterated | Neutral | 2026-08-05 | $620.00 | +16.10% |
Citigroup | Reiterated | Neutral | 2026-08-05 | $268.00 | −49.80% |
Stifel | Reiterated | Buy | 2026-03-31 | — | — |
Piper Sandler | Reiterated | Neutral | 2026-02-09 | $750.00 | +40.40% |
BTIG | Reiterated | Buy | 2026-02-03 | $800.00 | +49.80% |
JP Morgan | Reiterated | Overweight | 2025-11-04 | $550.00 | +3.00% |
Morgan Stanley | Reiterated | Overweight | 2025-11-04 | $805.00 | +50.70% |
Leerink Partners | Reiterated | Outperform | 2025-07-17 | $785.00 | +46.90% |
B of A Securities | Reiterated | Neutral | 2025-04-21 | — | — |
Goldman Sachs | Reiterated | Buy | 2024-01-17 | $530.00 | −0.80% |
Atlantic Equities | Downgraded | Overweight → Neutral | 2023-08-02 | $600.00 | +12.30% |
Credit Suisse | Reiterated | Outperform | 2021-08-13 | — | — |
Guggenheim | Downgraded | Buy → Neutral | 2021-07-12 | — | — |
Stifel Nicolaus | Reiterated | Buy | 2019-07-22 | $775.00 | +45.10% |
Canaccord Genuity | Reiterated | Buy | 2019-05-02 | — | — |
Bank of America | Reiterated | Buy | 2018-11-02 | — | — |
PiperJaffray | Reiterated | Overweight | 2018-01-16 | — | — |
Aegis Capital | Reiterated | Sell | 2017-06-01 | — | — |
CL King | Reiterated | Neutral | 2016-04-01 | — | — |
Raymond James | Downgraded | Outperform → Market Perform | 2015-08-28 | — | — |
Feltl & Co. | Upgraded | Sell → Hold | 2015-07-23 | — | — |
Bank oferica | Reiterated | Buy | 2012-04-20 | — | — |
Institution
Barclays
Reiterated · Overweight · 2026-08-11
$710.00
+32.90%
UBS
Reiterated · Neutral · 2026-08-05
$620.00
+16.10%
Citigroup
Reiterated · Neutral · 2026-08-05
$268.00
−49.80%
Stifel
Reiterated · Buy · 2026-03-31
—
—
Piper Sandler
Reiterated · Neutral · 2026-02-09
$750.00
+40.40%
BTIG
Reiterated · Buy · 2026-02-03
$800.00
+49.80%
JP Morgan
Reiterated · Overweight · 2025-11-04
$550.00
+3.00%
Morgan Stanley
Reiterated · Overweight · 2025-11-04
$805.00
+50.70%
Leerink Partners
Reiterated · Outperform · 2025-07-17
$785.00
+46.90%
B of A Securities
Reiterated · Neutral · 2025-04-21
—
—
Goldman Sachs
Reiterated · Buy · 2024-01-17
$530.00
−0.80%
Atlantic Equities
Downgraded · Overweight → Neutral · 2023-08-02
$600.00
+12.30%
Credit Suisse
Reiterated · Outperform · 2021-08-13
—
—
Guggenheim
Downgraded · Buy → Neutral · 2021-07-12
—
—
Stifel Nicolaus
Reiterated · Buy · 2019-07-22
$775.00
+45.10%
Canaccord Genuity
Reiterated · Buy · 2019-05-02
—
—
Bank of America
Reiterated · Buy · 2018-11-02
—
—
PiperJaffray
Reiterated · Overweight · 2018-01-16
—
—
Aegis Capital
Reiterated · Sell · 2017-06-01
—
—
CL King
Reiterated · Neutral · 2016-04-01
—
—
Raymond James
Downgraded · Outperform → Market Perform · 2015-08-28
—
—
Feltl & Co.
Upgraded · Sell → Hold · 2015-07-23
—
—
Bank oferica
Reiterated · Buy · 2012-04-20
—
—
One row per institution · price target from the firm's latest published target
StockOtter · stockotter.space